Net income for the three months ended March 31, 2026, increased by 61% to $24.2 million, up from $15.1 million in the prior year period. Revenue grew by 1% to $328.5 million for Q1 2026, compared to $324.0 million in Q1 2025, with both fertility and pharmacy benefits solutions contributing to the increase. Gross profit rose by 10% to $83.1 million, and gross margin expanded by 190 basis points to 25.3% for the quarter, attributed to efficiencies in care management services and reduced stock-based compensation. Operating expenses decreased by 8% overall, with sales and marketing down 5% and general and administrative down 9%, primarily due to lower stock-based compensation expense. The company served 595 clients and approximately 7.179 million members as of March 31, 2026, an increase from 555 clients and 6.689 million members as of December 31, 2025. Assisted Reproductive Treatment (ART) cycles decreased slightly to 15,647 in Q1 2026 from 16,160 in Q1 2025, influenced by the non-renewal of a large client in 2025. Member utilization rates for all fertility and family building services increased to 0.56% for all members and 0.48% for female-only members in Q1 2026. The $200 million share repurchase program authorized in November 2025 was completed as of March 31, 2026, with 5,511,824 shares repurchased at an average price of $21.13. Cash and cash equivalents increased to $131.6 million as of March 31, 2026, from $112.2 million at December 31, 2025, while marketable securities decreased to $93.5 million from $197.9 million.